A Phase 4 interventional study of RAD001 and Exemestane in Oestrogen Receptor Positive Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.
Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 43rd largest by enrollment, is one of 11 that started in 2013, is one of 2 in phase 4, and was the 38th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
MedSIR · Sites in Austria, Brazil, Czechia and 6 more countries
Ages 18+
Fudan University · Sites in China
Ages 18–70 · Women only
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 17 · Phase 4 2
First in 2005; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 55 across the 78 interventional studies. Of the 57 that completed or were terminated, 35 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 106th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2013, is one of 17 in phase 4, and was the 95th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing everolimus in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT06382948Phase 3MedSIRElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 78 studies testing everolimus in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Determine the overall response rate (ORR) at 48 weeks to everolimus (RAD001, 10mg daily p.o.) and exemestane (25mg daily p.o.) treatment in postmenopausal women with oestrogen receptor positive breast cancer who have previous experienced recurrence or progression on non-steroidal aromatase inhibitor (NSAI) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women. The investigator must confirm postmenopausal status. Postmenopausal status is defined either by:
Disease progression following prior therapy with NSAI, defined as:
Note: Non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. Other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to enrollment.
Patients must have:
Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of
(INR) ≤ 2 .
Total serum ≤ 1.5 × ULN (≤ 3 × ULN for patients known to have Gilbert Syndrome)
Serum creatinine ≤ 1.5 × ULN
Exclusion Criteria:
Prolonged systemic corticosteroid treatment during study, except for topical applications (e.g. rash),inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) should not be given. However:
Any severe and / or uncontrolled medical conditions such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
Drug: RAD001 · Drug: Exemestane
All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Also known as: Everolimus
All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.
Time frame: At 48 weeks
Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Treatment success is defined as: The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.
Time frame: At 48 weeks
Progression-free Survival (PFS) Events as Per Investigators - FAS
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.
Time frame: Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks
Progression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.
Time frame: Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks
Progression-free Survival (PFS) - % Event-free Probability Estimate - FAS
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review. The PFS was analyzed using the Kaplan Meier method.
Time frame: Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks
Overall Survival (OS) Events (Number of Deaths) - FAS
Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. Time to median OS was not estimable.
Time frame: Start of treatment to the date of death up to approximately 48 weeks
Overall Survival (OS) - % Event-free Probability Estimate - FAS
Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.
Time frame: Start of treatment to the date of death up to approximately 48 weeks
Change From Baseline EORTC Quality of Life Questionnaire of Cancer Patients QLQ-C30 at Each Time Point
The QLQ-C30 is composed of multi-item scales and single-item measures including 5 functional scales, 3 symptom scales, a global health status-QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. High scale score=higher response level; a high score for a functional scale=a healthy level of function, high score for the global health status/QoL=high quality of life but a high score for a symptom scale / item=high level of symptomatology/problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations
Time frame: Baseline 12,24,36,48 weeks
Percentage of Patient Responses in EuroQoL 5-dimension Questionnaire - FAS
EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D descriptive system is comprised of the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Percentage of participants' responses were presented by visits. Results should be interpreted with caution as the numbers of patients with available data over time were limited.
Time frame: Baseline 12,24,36,48 weeks
Change From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS
EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). For the visual analogue scale, participants draw a line from a box to the point on the thermometer-like scale corresponding to their health state, 0-100 (100 = Best health state). Weights are used to score the responses to the 5 domains, with scores ranging from 0 to 1 (where a score of 1 represents a perfect state). Scores for the visual analogue scale reflect the position where participant's line crosses the thermometer-like scale. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations
Time frame: Baseline 12,24,36,48 weeks
| Milestone | Everolimus and Exemestane |
|---|---|
| Started | 52 |
| Full analysis set (fas) | 49 |
| Safety analysis set (saf) | 49 |
| Completed | 9 |
| Not completed | 43 |
| Withdrew: Disease progression | 26 |
| Withdrew: Adverse event | 8 |
| Withdrew: Death | 3 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: >1 dose of study drug | 3 |
The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.
| participants | Everolimus and Exemestane |
|---|---|
| Patients with measurable disease at baseline | 39 |
| Patients with non-measurable disease at baseline | 10 |
| Best at WK 48 - Complete Response (CR) | 0 |
| Best at WK 48 - Partial Response (PR) | 7 |
| Best at WK 48 - Stable Disease (SD) | 18 |
| Best at WK 48 - Progressive Disease (PD) | 15 |
| Unknown | 1 |
| Missing | 8 |
The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Treatment success is defined as: The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.
| Percentage of participants | Everolimus and Exemestane |
|---|---|
| Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | 14.3 (6.0 to 27.0) |
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.
| Number of events | Everolimus and Exemestane |
|---|---|
| Deaths | 8 (12.71 to 34.29) |
| Progression of disease | 25 |
| Number of censored observations | 16 |
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.
| weeks | Everolimus and Exemestane |
|---|---|
| Progression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS | 23.6 (12.71 to 34.29) |
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review. The PFS was analyzed using the Kaplan Meier method.
| Percentage of participants | Everolimus and Exemestane |
|---|---|
| Event free at 12 weeks | 67.9 (51.82 to 79.56) |
| Event free at 24 weeks | 49.1 (32.98 to 63.44) |
| Event free at 36 weeks | 28.9 (15.42 to 43.87) |
| Event free at 48 weeks | 18.4 (7.38 to 33.19) |
Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. Time to median OS was not estimable.
| Number of events | Everolimus and Exemestane |
|---|---|
| Deaths | 8 (12.71 to 34.29) |
| Number of censored observations | 41 |
Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.
| Percentage of participants | Everolimus and Exemestane |
|---|---|
| Event free at 12 weeks | 93.3 (80.57 to 97.78) |
| Event free at 24 weeks | 83.9 (66.92 to 92.60) |
| Event free at 36 weeks | 74.2 (53.02 to 86.88) |
| Event free at 48 weeks | 74.2 (53.02 to 86.88) |
The QLQ-C30 is composed of multi-item scales and single-item measures including 5 functional scales, 3 symptom scales, a global health status-QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. High scale score=higher response level; a high score for a functional scale=a healthy level of function, high score for the global health status/QoL=high quality of life but a high score for a symptom scale / item=high level of symptomatology/problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations
| scores | Week 12 | Week 24 | Week 36 | Week 48 |
|---|---|---|---|---|
| Global health status/QoL | -9.0 ± 22.04 | -3.6 ± 19.71 | 1.9 ± 16.37 | -8.3 ± 22.48 |
| Physical functioning | -5.1 ± 19.16 | -1.0 ± 14.52 | 4.9 ± 13.79 | -10.8 ± 29.97 |
| Role functioning | -4.5 ± 33.19 | 3.1 ± 23.74 | 8.3 ± 23.03 | -12.3 ± 30.52 |
| Emotional functioning | 2.6 ± 21.36 | -3.1 ± 14.87 | 7.5 ± 9.90 | 0.6 ± 21.59 |
| Cognitive functioning | -8.6 ± 21.37 | -5.2 ± 17.97 | 1.3 ± 22.01 | -3.7 ± 21.35 |
| Social functioning | -9.9 ± 25.00 | -9.4 ± 24.32 | 3.8 ± 15.45 | -14.7 ± 31.74 |
| Fatigue | 8.6 ± 26.92 | 9.5 ± 15.93 | 0.9 ± 16.64 | 7.3 ± 24.66 |
| Nausea/ vomiting | -1.2 ± 15.96 | 2.9 ± 16.91 | -3.8 ± 15.45 | -2.4 ± 23.88 |
| Pain | 1.2 ± 26.12 | 3.9 ± 24.67 | -1.3 ± 20.93 | 0.6 ± 24.64 |
| Dyspnea | 18.5 ± 37.36 | 8.3 ± 25.82 | 2.6 ± 25.32 | 10.7 ± 27.30 |
| Insomnia | 3.7 ± 26.69 | 2.0 ± 29.98 | 0 ± 23.57 | -3.6 ± 37.78 |
| Appetite loss | 30.9 ± 40.22 | 23.5 ± 28.30 | 12.8 ± 28.99 | 16.7 ± 35.72 |
| Constipation | 4.9 ± 32.95 | 11.8 ± 28.73 | 10.3 ± 21.01 | 8.3 ± 19.51 |
| Diarrhea | 4.9 ± 25.66 | 8.3 ± 37.52 | -5.1 ± 22.96 | 7.4 ± 28.24 |
| Financial problems | -1.2 ± 21.64 | -10.4 ± 26.44 | -10.3 ± 21.01 | -2.6 ± 18.67 |
EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D descriptive system is comprised of the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Percentage of participants' responses were presented by visits. Results should be interpreted with caution as the numbers of patients with available data over time were limited.
| Percentage of participants | Day 1 | Week 12 | Week 24 | Week 36 | Week 48 |
|---|---|---|---|---|---|
| Mobility-no problem | 38.8 | 20.4 | 18.4 | 14.3 | 16.3 |
| Mobility-slight problem | 18.4 | 14.3 | 10.2 | 8.2 | 16.3 |
| Mobility-moderate problem | 32.7 | 20.4 | 8.2 | 2.0 | 14.3 |
| Mobility-severe problem | 6.1 | 2.0 | 0 | 2.0 | 6.1 |
| Mobility-unable to walk | 0 | 0 | 0 | 0 | 4.1 |
| Self-care - no problem | 69.4 | 44.9 | 34.7 | 24.5 | 40.8 |
| Self-care - slight problem | 18.4 | 4.1 | 0 | 0 | 10.2 |
| Self-care - moderate problem | 6.1 | 8.2 | 2.0 | 2.0 | 4.1 |
| Self-care -severe problem | 2.0 | 0 | 0 | 0 | 2.0 |
| Self-care - unable | 0 | 0 | 0 | 0 | 0 |
| Usual activities - no problems | 30.6 | 14.3 | 22.4 | 14.3 | 18.4 |
| Usual activities - slight problems | 22.4 | 16.3 | 2.0 | 8.2 | 14.3 |
| Usual activities - moderate problems | 28.6 | 22.4 | 12.2 | 2.0 | 12.2 |
| Usual activities - severe problems | 10.2 | 4.1 | 0 | 2.0 | 6.1 |
| Usual activities -unable to do | 4.1 | 0 | 0 | 0 | 6.1 |
| Pain/discomfort - none | 20.4 | 14.3 | 10.2 | 12.2 | 18.4 |
| Pain/discomfort - slight | 30.6 | 16.3 | 18.4 | 8.2 | 20.4 |
| Pain/discomfort - moderate | 40.8 | 22.4 | 8.2 | 6.1 | 14.3 |
| Pain/discomfort - severe | 4.1 | 4.1 | 0 | 0 | 4.1 |
| Pain/discomfort - extreme | 0 | 0 | 0 | 0 | 0 |
| Anxiety/depression - none | 44.9 | 22.4 | 18.4 | 16.3 | 22.4 |
| Anxiety/depression - slight | 34.7 | 22.4 | 12.2 | 10.2 | 20.4 |
| Anxiety/depression - moderate | 16.3 | 12.2 | 6.1 | 0 | 8.2 |
| Anxiety/depression - severe | 0 | 0 | 0 | 0 | 6.1 |
| Anxiety/depression - extreme | 0 | 0 | 0 | 0 | 0 |
EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). For the visual analogue scale, participants draw a line from a box to the point on the thermometer-like scale corresponding to their health state, 0-100 (100 = Best health state). Weights are used to score the responses to the 5 domains, with scores ranging from 0 to 1 (where a score of 1 represents a perfect state). Scores for the visual analogue scale reflect the position where participant's line crosses the thermometer-like scale. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations
| units on a scale | Week 12 | Week 24 | Week 36 | Week 48 |
|---|---|---|---|---|
| Change From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS | -7.9 ± 18.98 | -6.1 ± 12.47 | -6.3 ± 10.03 | -11.6 ± 22.58 |
Collected over Adverse Events (AEs) are collected from the First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus + Exemestane | — | 22/49 (44.9%) | 49/49 (100%) |
| Event | Everolimus + Exemestane |
|---|---|
| Lower respiratory tract infectionInfections and infestations | 4/49 |
| Confusional statePsychiatric disorders | 3/49 |
| AnaemiaBlood and lymphatic system disorders | 2/49 |
| VomitingGastrointestinal disorders | 2/49 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/49 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/49 |
| Spinal cord compressionNervous system disorders | 2/49 |
| Renal failureRenal and urinary disorders | 2/49 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/49 |
| Pericardial effusionCardiac disorders | 1/49 |
| Event | Everolimus + Exemestane |
|---|---|
| DiarrhoeaGastrointestinal disorders | 22/49 |
| FatigueGeneral disorders | 22/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/49 |
| RashSkin and subcutaneous tissue disorders | 18/49 |
| Mucosal inflammationGeneral disorders | 17/49 |
| Decreased appetiteMetabolism and nutrition disorders | 16/49 |
| NauseaGastrointestinal disorders | 14/49 |
| Mouth ulcerationGastrointestinal disorders | 11/49 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/49 |
| AnaemiaBlood and lymphatic system disorders | 8/49 |
FAS
| Age, Continuous(years) | Everolimus and Exemestane |
|---|---|
| Mean | 61.3 ± 8.71 |
| Sex: Female, Male(Participants) | Everolimus and Exemestane |
|---|---|
| Female | 49 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Everolimus and Exemestane |
|---|---|
| Caucasian | 48 |
| Other | 1 |
| Weight(kg) | Everolimus and Exemestane |
|---|---|
| Mean | 71.1 ± 15.44 |
Ran from Jan 2013 to primary completion in Aug 2016, 42 months.
Results were first posted in Apr 2019, 2 years 7 months after primary completion.
Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus